In this randomized trial of Goserelin for ovarian protection during adjuvant chemotherapy in women with breast cancer, Leonard et al. concluded that ovarian suppression may reduce likelihood of amenorrhea and Premature Ovarian Insufficiency (POI) in those aged <40 years [1]. However, we are concerned about the validity of these conclusions.

中文翻译：

---

戈舍瑞林不能保护卵巢功能免受化疗引起的损伤。

在这项 Goserelin 用于乳腺癌女性辅助化疗期间卵巢保护的随机试验中，Leonard 等人。得出的结论是，卵巢抑制可能会降低 40 岁以下人群的闭经和卵巢早衰 (POI) 的可能性 [1]。然而，我们担心这些结论的有效性。